Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1

Interventions

Gemcitabine 9pembrolizumab 7Cisplatin 5enfortumab vedotin 4atezolizumab 4Trastuzumab 4Mitomycin 4Carboplatin 4Sunitinib 3Pemetrexed 3dodecyl maltoside 2cabozantinib 2Water 2Sugammadex 2Standard of Care 2Saline Solution 2Paclitaxel 2Nivolumab 2Neostigmine 2Docetaxel 2Cetuximab 2Bevacizumab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1vinflunine 1valrubicin 1tucatinib 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × Gels × Genitourinary × Clear all
NCT02307487 2017-06-16

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

UroGen Pharma Ltd.

Phase 2 Completed
14 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡